Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms

Figure 1 Management of tyrosine kinase inhibitor-induced hepatotoxicity according to European LeukemiaNet recommendations. ^aAdverse events may require specific treatment; ^bAlternatively, continue TKI for 1 wk with appropriate management of adverse event. If no resolution is achieved, withhold TKI until liver toxicity is grade < 2 and monitor weekly. TKI: Tyrosine kinase inhibitor.